Drug Profile
Research programme: nitric oxide therapeutics - Novan Inc
Alternative Names: CR 2005; CR 2016; Nitric Oxide Advanced Healing technology - Novan Therapeutics; NOAH technology - Novan Therapeutics; NVN 4428; NVN-4000Latest Information Update: 24 Sep 2021
Price :
$50
*
At a glance
- Originator Novan Inc
- Class Anti-infectives; Anti-inflammatories; Antiacnes; Antiandrogens; Antibacterials; Antibronchitics; Antifibrotics; Antifungals; Antihypertensives; Antineoplastics; Antituberculars; Antivirals; Cardiovascular therapies; Diagnostic agents; Foot disorder therapies; Free radicals; Nitrogen oxides; Non-opioid analgesics; Skin disorder therapies; Small molecules; Vascular disorder therapies; Vasodilators
- Mechanism of Action Angiogenesis inducing agents; Nitric oxide stimulants; Reactive oxygen species modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Burns; Onychomycosis; Staphylococcal infections; Wound infections; Wounds
Most Recent Events
- 25 Oct 2018 Novan and University of Alabama at Birmingham extend research collaboration for nitric oxide-releasing compounds on HPV infections
- 18 Oct 2017 Nitric oxide licensed to Novan worldwide for the treatment of Human-papillomavirus-infections
- 22 Nov 2016 Discontinued - Preclinical for Wounds in USA (Topical)